Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Net Income for 5 consecutive years, with $24.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 3330.95% year-over-year to $24.4 million, compared with a TTM value of $69.2 million through Dec 2025, up 297.46%, and an annual FY2025 reading of $69.2 million, up 297.46% over the prior year.
  • Net Income was $24.4 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $18.4 million in the prior quarter.
  • Across five years, Net Income topped out at $224.1 million in Q3 2022 and bottomed at -$49.5 million in Q1 2021.
  • Average Net Income over 5 years is $6.2 million, with a median of -$8.1 million recorded in 2023.
  • The sharpest move saw Net Income tumbled 126.1% in 2024, then soared 3330.95% in 2025.
  • Year by year, Net Income stood at -$44.1 million in 2021, then skyrocketed by 110.12% to $4.5 million in 2022, then surged by 1751.2% to $82.6 million in 2023, then tumbled by 100.92% to -$756000.0 in 2024, then skyrocketed by 3330.95% to $24.4 million in 2025.
  • Business Quant data shows Net Income for KNSA at $24.4 million in Q4 2025, $18.4 million in Q3 2025, and $17.8 million in Q2 2025.